Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient

Benzer Materyaller

• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  Yazar:: Wu, Shang-Gin, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
  Yazar:: Yamaguchi, Norihiro, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor
  Yazar:: Luo, Jia, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
  Yazar:: Miyoshi, Seigo, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  Yazar:: Chen, Zhi-Yong, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)